CD10 expression in urothelial bladder carcinomas: Staining patterns and relationship with pathologic parameters;Ürotelyal mesane karsinomlarında CD10 ekspresyonu: Boyanma paterni ve patolojik parametreler ile ilişkisi

Turkish Journal of Medical Sciences

Volumn 40, Issue 2, 2010, Pages 177-184

  Onak Kandemir, Nilüfer ^a   Bahadir, Burak ^a   Doǧan Gün, Banu ^a   Yurdakan, Gamze ^a   Karadayi, Nimet ^b   Özdamar, Şükrü Oǧuz ^a  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^b Kartal Lutfi Kirdar Training and Research Hospital   (Turkey)

Author keywords

Bladder; Cd10; Immunohistochemistry; Papillary urothelial carcinoma

Indexed keywords

CELL MEMBRANES; PATHOLOGY;

BLADDER; CD10; IMMUNOHISTOCHEMICAL STAINING; IMMUNOHISTOCHEMISTRY; LYMPHOVASCULAR INVASIONS; PROGNOSTIC MARKERS; STATISTICALLY SIGNIFICANT DIFFERENCE; UROTHELIAL CARCINOMA;

TUMORS;

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 77952489362     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-0805-68     Document Type: Article

References (24)

1. Shipp MA, Stefano GB, D'Adamio L, Switzer SN, Howard FD, Sinisterra J et al. Downregulation of enkephalin-mediated inflammatory responses by CD10/neutral endopeptidase 24. 11. Nature 1990; 347: 394-396.
2. Shipp MA, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood 1984; 82:1052-1070.
3. Arber DA, Weiss LM. CD10: a review. Appl Immunohistochem Mol Morphol 1997; 5: 125-140.
4. Ritz J, Pesando JM, Notis-McConarty J, Lazarus H, Schlossman F. A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature 1980; 283: 583-585.
5. Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and bcl-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000; 24: 846-852.
6. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Am J Clin Pathol 2000; 113: 374-382.
7. Metzgar RS, Borowitz MJ, Jones NH, Dowell BL. Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues. J Exp Med 1981; 154: 1249-1254.
8. Kaufmann O, Flath B, Späth-Schwalbe E, Possinger K, Dietel M. Immunohistochemical detection of CD10 with monoclonal antibody 56C6 on paraffin sections. Am J Clin Pathol 1999; 111: 117-122.
9. Mc Intosh GG, Lodge AJ, Watson P, Hall AG, Wood K, Anderson JJ et al. NCL-CD10-270: a new monoclonal antibody recognizing CD10 in paraffin-embedded tissue. Am J Pathol 1999; 154: 77-82.
10. Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D, et al. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest 2000; 106: 1399-1407.
11. Dai J, Shen RQ, Sumitomo M, Goldberg JS, Geng Y, Navarro D et al. Tumor suppressive effects of neutral endopeptidase in androgen-independent prostate cancer. Clin Cancer Res 2001; 7: 1370-1377.
12. Ganju RK, Sunday ME, Tsarwhas DG, Card A, Shipp MA. CD10/ NEP in non-small cell lung carcinomas: relationship to cellular proliferation. J Clin Invest 1994; 94 (5): 1784-1791.
13. Ogawa H, Iwaya K, Izumi M, Kroda M, Serizawa H, Koyanagi Y et al. Expression of CD10 by stromal cells during colorectal tumor development. Hum Pathol 2002; 33: 806-811.
14. Iwaya K, Ogawa H, Izumi M, Kuroda M, Serizawa H, Koyanagi Y et al. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch 2002; 440: 589-593.
15. Kanitakis J, Narvaez D, Claudy A. Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin. Melanoma Res 2002; 12: 241-244.
16. Bircan S, Candir O, Kapucuoglu N. CD10 expression in urothelial bladder carcinomas: A pilot study. Urol Int 2006; 77: 107-113.
17. Murali R, Delprado W. CD10 i{dotless}mmunohistochemical staining in urothelial neoplasms. Am J Clin Pathol 2005; 124: 371-379.
18. Koiso K, Akaza H, Ohtani M, Miyanaga N, Aoyagi K. A new tumor marker for bladder cancer. Int J Urol 1994; 1: 33-36.
19. Chu PG, Arber DA, Weiss LM, Chang KL. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol 2001; 14(5): 465-71.
20. Kim MK, Kim S. Immunhistochemical profile of common epithelial neoplasms arising in the kidney. Appl Immunohistochem Mol Morphol 2002; 154: 77-82.
21. R, Jones PA, Sidransky D, Hartmann A, Schmitz-Drager BC, Helpap B, et al. Genetics and predictive factors of noninvasive urothelial neoplasias. In: Eble JN, Sauter G, Epstein JI, et al, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004:120-123. World Health Organization Classification of Tumours.
22. Cheng L, Neumann RM, Nehra A, Spotts BE, Weaver AL, Bostwick DG. Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. Cancer 2000; 88: 1663-1670.
23. A, Sauter G, Gasser T, Hartmann A, Schmitz-Drager BC, Helpap B, et al. Infiltrating urothelial carcinoma. In: Eble JN, Sauter G, Epstein JI, et al, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004: 93-109. World Health Organization Classification of Tumours.
24. Lee R, Droller MJ. The natural history of bladder cancer: implications for therapy. Urol Clin N Am 2000; 27: 1-13.